Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Eli Lilly Could Be Making The Next Ozempic, but Should You Buy the Stock?

TheMotleyFool

0 0

Eli Lilly Could Be Making The Next Ozempic, but Should You Buy the Stock?: https://g.foolcdn.com/editorial/images/738052/woman-lab-science-research-stem1.jpg

Since the launch of its drug Mounjaro last year, it's clear that Eli Lilly (NYSE: LLY) has become a strong competitor to Novo Nordisk (NYSE: NVO) and its early dominance in the market for medicines that treat obesity and type 2 diabetes.

And now, Eli Lilly could have a further trick up its sleeve. While Novo Nordisk's portfolio includes household names like Ozempic, Rybelsus, and Wegovy, Eli Lilly's retatrutide -- currently in clinical trials -- might be an even bigger winner.

So does that make Eli Lilly's stock worth buying today? Let's dive in and see what's going on.

Source Fool.com

Like: 0

LLY

Share